Tech Company Financing Transactions
Neuraltus Pharmaceuticals Funding Round
On 3/26/2009, Neuraltus Pharmaceuticals raised $17 million in Series A financing from Adams Harkness Ventures, Latterell Venture Partners and VantagePoint Capital Partners.
Transaction Overview
Company Name
Announced On
3/26/2009
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2479 E. Bayshore Rd. 220
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Website
Email Address
Overview
Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing innovative small molecule therapeutics for the treatment of neurodegenerative disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Whelan
Chief Medical Officer
Gil Block
Chief Scientific Officer
Michael McGrath
Browse more venture capital transactions:
Prev: 3/26/2009: Lifefactory venture capital transaction
Next: 3/26/2009: Thumbplay venture capital transaction
Share this article
News on VC Transactions
We report on tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs